ARTICLE
11 August 2017

FDA Outlines The New Digital Health Innovation Action Plan And Software Precertification Pilot Program

MW
McDermott Will & Emery

Contributor

McDermott Will & Emery logo
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With more than 1,100 lawyers across several office locations worldwide, our team works seamlessly across practices, industries and geographies to deliver highly effective solutions that propel success.
Last Tuesday afternoon, the US Food and Drug Administration (FDA) held a webinar to outline a recently-published Digital Health Innovation Action Plan (Plan).
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

Last Tuesday afternoon, the US Food and Drug Administration (FDA) held a webinar to outline a recently-published Digital Health Innovation Action Plan (Plan). In the Plan, the agency recognized that the traditional regulatory approach toward moderate and high risk medical devices is not well suited for the fast-paced, iterative design, development and type of validation used for digital health software products today. Going forward, the agency plans to explore an innovative approach to regulating these types of products. The approach contains three primary prongs: (1) the issuance of new guidance, (2) the Digital Health Software Precertification Program and (3) an internal expansion of FDA's digital health capabilities.

The webinar was presented by Bakul Patel, Associate Director for Digital Health at FDA. At least 905 attendees logged in to the webinar.

Below are a few important takeaways.

  • The presentation provided a high-level overview of the digital health space, the existing regulatory framework, and regulatory changes necessary under the 21st Century Cures Act.
  • For digital health products, FDA is moving away from the review of one product at a time toward a "reimagined approach" with marketing authorizations based on a developer's culture of quality and organizational excellence.
  • The purpose of the pilot program is for FDA to learn about industry best practices (e.g., management, development, validation, deviation) and key performance indicators (KPIs) or other measures. These best practices and measures will inform the development of the future precertification program regulatory pathway.
  • Statements of Interest for participation in the pilot program should demonstrate that the participant is willing to share in the spirit of learning and make an impression that the company is excellent.
  • Participation in the pilot program does not protect a company from enforcement activities that result from a pilot site visit, but Bakul Patel stated that chosen participants will be "excellent" and, as an extension, presumably will not have compliance issues.

For more details about the Plan and pilot program, check out our latest article.

Details about the webinar, including the presentation slide deck, may be found here.

FDA Outlines The New Digital Health Innovation Action Plan And Software Precertification Pilot Program

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More